ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2023, Vol. 15 ›› Issue (2): 129-132.doi: 10.3969/j.issn.1674-3865.2023.02.008

• 综述 • 上一篇    下一篇

吡仑帕奈单药治疗儿童癫痫的研究进展

吴玫, 唐永在, 乔佩, 董琰   

  1. 063000 河北 唐山，华北理工大学附属唐山市妇幼保健院神经内科
  • 收稿日期:2022-12-03 出版日期:2023-04-25 上线日期:2023-04-25
  • 通讯作者: 董琰，E-mail：dongyan012000@126.com

Research progress of Perampanel monotherapy in the treatment of epilepsy in children

WU Mei, TANG Yongzai, QIAO Pei, DONG Yan   

  1. Department of Neurology, Tangshan Maternal and Child Health Hospital Affiliated to North China University of Science and Technology, Tangshan 063000, China

  • Received:2022-12-03 Published:2023-04-25 Online:2023-04-25
  • Contact: DONG Yan，E-mail：dongyan012000@126.com

PDF (PC)

213

摘要： 吡仑帕奈作为首个被批准使用的高选择性、非竞争性α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体拮抗剂，目前已经在中国被批准治疗成人和4岁及以上儿童的局灶性癫痫(伴或不伴进展为双侧强直-阵挛发作)。该药在国内上市较晚，且多用于成人及儿童的添加治疗，单药治疗儿童癫痫中的应用经验较少。文章就国内外有关吡仑帕奈的作用机制、药代动力学、单药治疗儿童癫痫的疗效及安全性等作一综述，以期为临床医生提供参考

关键词: 癫痫, 吡仑帕奈, 单药, 疗效, 安全性

Abstract: Perampanel(PER), as the first highly selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxy-5-methyl -4-isooxazolpropionic acid (AMPA) receptor antagonist approved for use, is currently approved in China for the treatment of focal epilepsy (with or without progression to bilateral tonic-clonic seizures) in adults and children aged 4 years and older. This drug was marketed late in China, and was mostly used for additive therapy in adults and children. There is little experience in the application of monotherapy for children's epilepsy. This article reviewed the mechanism of action, pharmacokinetics, efficacy and safety of PER in the treatment of childhood epilepsy at home and abroad, in order to provide reference for clinicians. 

Key words:

Epilepsy, Perampanel, Monotherapy, Efficacy, Safety